Relapsed/Refractory Multiple Myeloma: Targeted Therapy and BCMA

home / clinical-consult / relapsed-refractory-multiple-myeloma-targeted-therapy-and-bcma

Sagar Lonial, MD, FACP, explains the various ways to target and treat relapsed/refractory multiple myeloma, specifically focusing on BCMA and belantamab mafoditin as therapeutic agents.

Treatment Goals and Options for RRMM

EP. 1: Treatment Goals and Options for RRMM

Sagar Lonial, MD, FACP
May 3rd 2021

A multiple myeloma expert introduces and defines relapsed/refractory myeloma and discusses typical treatment strategies.

Considerations for Selecting Therapy in RRMM

EP. 2: Considerations for Selecting Therapy in RRMM

Sagar Lonial, MD, FACP
May 3rd 2021

Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.

BCMA as a Therapeutic Target for RRMM

EP. 3: BCMA as a Therapeutic Target for RRMM

May 3rd 2021

Dr Sagar Lonial, MD, FACP, comments on BCMA as a potential therapeutic target for multiple myeloma.

The DREAMM-2 Trial

EP. 4: The DREAMM-2 Trial

Sagar Lonial, MD, FACP
May 3rd 2021

A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.

BCMA-Targeted Therapies for NDMM

EP. 5: BCMA-Targeted Therapies for NDMM

Sagar Lonial, MD, FACP
May 3rd 2021

Sagar Lonial, MD, FACP, provides insight on the potential role of BCMA-targeted therapies for newly diagnosed patients with multiple myeloma.

Future Directions in MM Therapeutics

EP. 6: Future Directions in MM Therapeutics

Sagar Lonial, MD, FACP
May 3rd 2021

Dr Sagar Lonial, MD, FACP, shares his thoughts on the future of targeted therapies for patients with multiple myeloma.